Moderna's Cancer Vaccine Worked -- and the Stock Plunged Anyway. Here's What Investors Are Missing.
Moderna's melanoma vaccine plus Keytruda cut the risk of recurrence or death by 42% in Phase 3, yet the stock sank. Here's why.
Moderna's experimental cancer vaccine, intismeran autogene, achieved positive Phase 3 results when tested alongside Merck's Keytruda, reducing the risk of cancer recurrence or death by 42% compared to keytruda alone, but the stock still plummeted. Investors might be overlooking the broader opportunity presented by the vaccine's personalized mRNA technology, which could expand into various cancer types.
Despite initial disappointment due to high expectations, analysts have softened their views, recognizing the vaccine's significant improvement over Keytruda alone. The vaccine's safety profile is also favorable, with serious adverse events occurring in only around 10% of patients. Moreover, preclinical data suggests potential effectiveness in other cancer types, such as renal cell carcinoma, bladder cancer, and non-small cell lung cancer.
While Moderna stock trades at a high valuation, the company's long-term business prospects remain promising, and dismissing it based on a single trial result could be a mistake.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.